Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the ...

Jan 6 (Reuters) - Eli ‌Lilly ​is in advanced ‌talks to buy Ventyx ​Biosciences for more than $1 billion, ‍the Wall Street ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Eli Lilly (NYSE: LLY) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Indiana Attorney General Todd Rokita on Monday announced a new lawsuit against Indianapolis-based drug maker Eli Lilly and Co ...

Shares of Ventyx Biosciences gained after The Wall Street Journal reported that the company is in advanced talks to be acquired by Eli Lilly for about $1 billion. Ventyx shares were up 5.2%, to $8.23, ...

Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be ...

It’s the latest move in the race by drug companies to corner more of the highly lucrative obesity drug market.

Attorney General Todd Rokita is intensifying his efforts to lower insulin prices and improve healthcare affordability for ...

Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read ...